Imeik Technology Development Co (300896)

Currency in CNY
139.78
+1.06(+0.76%)
Delayed Data·
Earnings results expected in 10 days
300896 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
139.02140.10
52 wk Range
137.36209.00
Key Statistics
Bid/Ask
139.78 / 139.79
Prev. Close
138.72
Open
139.84
Day's Range
139.02-140.1
52 wk Range
137.36-209
Volume
816.12K
Average Volume (3m)
3.46M
1-Year Change
-20.0926%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
300896 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
186.16
Upside
+33.18%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral

Imeik Technology Development Co.,Ltd. engages in the research and development, production, and transformation of biomedical soft tissue repair materials in China. The company offers aesthetic medicine products, including cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere, poly facial implant thread, medical sodium hyaluronate-hydroxypropyl methylcellulose gel, sodium hyaluronate composite solution for injection, modified sodium hyaluronate gel for injection, and medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel. It also provides skin care products. Imeik Technology Development Co.,Ltd. was incorporated in 2004 and is based in Beijing, China.

Employees
1223
Market
China

Compare 300896 to Peers and Sector

Metrics to compare
300896
Peers
Sector
Relationship
P/E Ratio
28.7x37.1x−0.5x
PEG Ratio
−1.030.320.00
Price/Book
5.7x2.8x2.6x
Price / LTM Sales
16.7x6.9x3.2x
Upside (Analyst Target)
32.4%37.3%51.4%
Fair Value Upside
Unlock2.6%7.1%Unlock

Analyst Ratings

13 Buy
2 Hold
1 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 186.16
(+33.18% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Macquarie
Buy181.00+29.55%203.00MaintainOct 29, 2025
Morgan Stanley
Hold140.00+0.21%160.00MaintainOct 28, 2025
Macquarie
Buy203.00+45.30%219.00MaintainAug 19, 2025
Citi
Buy200.00+43.15%240.00MaintainApr 29, 2025
Macquarie
Buy219.00+56.75%245.00MaintainApr 25, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.87%
Dividend Yield
3.60%
Industry Median 1.74%
Annualized payout
5.00
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Oct 29, 2025
EPS / Forecast
1.01 / 1.44
Revenue / Forecast
566.00M / 744.27M
EPS Revisions
Last 90 days

300896 Income Statement

People Also Watch

387.95
300502
+1.03%
56.02
300037
+0.48%
38.31
300679
+2.82%
116.30
300724
+0.04%

FAQ

What Is the Imeik (300896) Stock Price Today?

The Imeik stock price today is 139.78 CNY.

What Stock Exchange Does Imeik Trade On?

Imeik is listed and trades on the Shenzhen Stock Exchange.

What Is the Stock Symbol for Imeik?

The stock symbol for Imeik is "300896."

Does Imeik Pay Dividends? What’s The Current Dividend Yield?

The Imeik dividend yield is 3.6%.

What Is the Imeik Market Cap?

As of today, Imeik market cap is 41.81B CNY.

What Is Imeik's Earnings Per Share (TTM)?

The Imeik EPS (TTM) is 4.87.

When Is the Next Imeik Earnings Date?

Imeik will release its next earnings report on Mar 20, 2026.

From a Technical Analysis Perspective, Is 300896 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Imeik Stock Split?

Imeik has split 2 times.

How Many Employees Does Imeik Have?

Imeik has 1223 employees.

What is the current trading status of Imeik (300896)?

As of Mar 10, 2026, Imeik (300896) is trading at a price of 139.78 CNY, with a previous close of 138.72 CNY. The stock has fluctuated within a day range of 139.02 CNY to 140.10 CNY, while its 52-week range spans from 137.36 CNY to 209.00 CNY.

What Is Imeik (300896) Price Target According to Analysts?

The average 12-month price target for Imeik is 186.16 CNY, with a high estimate of 228 CNY and a low estimate of 130 CNY. 13 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +33.18% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.